TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21316768

Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic psychotherapy
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Psychoanalysis
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Solution-focused therapy
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Short-term therapies
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Long-term therapy
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 367
Study: 19584651

Group type: EXPERIMENTAL
Intervention: Low-dose recombinant tissue plasminogen activator (rt-PA) 50 mg with concomitant intravenous heparinization
Number of subjects: 52

Group type: COMPARATOR
Intervention: Hemodilution
Number of subjects: 52
Study: 17541702

Group type: EXPERIMENTAL
Intervention: Division of ilioinguinal nerve
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Division of genital nerve
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Division of iliohypogastric nerve
Number of subjects: 172

Group type: COMPARATOR
Intervention: All three nerves preserved
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Significant chronic pain cases
Number of subjects: 172
Study: 15215801

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 5010

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5010
Study: 11451842

Group type: EXPERIMENTAL
Intervention: Two-Chamber Open Drainage System (TCOS)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Complex Closed Drainage System (CCDS)
Number of subjects: 224
Study: 10078083

Group type: EXPERIMENTAL
Intervention: 1 mg ibutilide
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: 2 mg ibutilide
Number of subjects: 308

Group type: COMPARATOR
Intervention: 1.5 mg/kg DL-sotalol
Number of subjects: 308

Group type: COMPARATOR
Intervention: DL-sotalol
Number of subjects: 308
Study: 7978437

Group type: COMPARATOR
Intervention: Fentanyl 75 micrograms/h
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fentanyl 25 micrograms/h plus clonidine 0.3 micrograms.kg‐1.h‐1
Number of subjects: 32
Study: 2514457

Group type: EXPERIMENTAL
Intervention: Two puffs of a mixture of 1 mg disodium cromoglycate and 0.5 mg of reproterol hydrochloride administered by metered dose inhaler through Volumatic spacer
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Two puffs of a mixture of 1 mg disodium cromoglycate and 0.5 mg of reproterol hydrochloride administered by metered dose inhaler through Nebuhaler spacer
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Two puffs of a mixture of 1 mg disodium cromoglycate and 0.5 mg of reproterol hydrochloride administered by metered dose inhaler through InspirEase spacer
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Two puffs of a mixture of 1 mg disodium cromoglycate and 0.5 mg of reproterol hydrochloride administered by metered dose inhaler through Synchron‐Aerosol spacer
Number of subjects: 18
Study: 31009293

Group type: EXPERIMENTAL
Intervention: Virtual-Reality Endoscopy Trainer (VRET)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Live Dog Laboratory (LDL)
Number of subjects: 12
Study: 30047216

Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semaglutide 0.25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liraglutide, Dulaglutide, Exenatide extended-release
Number of subjects: 0
Study: 28329368

Group type: EXPERIMENTAL
Intervention: Daily TMP-SMX plus monthly dihydroartemisinin-piperaquine (DP)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Daily TMP-SMX alone
Number of subjects: 200
Study: 25946762

Group type: EXPERIMENTAL
Intervention: rilonacept
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 23404986

Group type: EXPERIMENTAL
Intervention: World Health Organization's Surgical Safety Checklist (SSC)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Control group (no SSC implementation)
Number of subjects: 575
Study: 21962313

Group type: EXPERIMENTAL
Intervention: Weight loss (≥ 5% and ≥ 20% body weight)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Weight gain
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Weight loss (≥ 20% body weight)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Weight change (stable or gained weight)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Weight management
Number of subjects: 208
Study: 18253120

Group type: EXPERIMENTAL
Intervention: Cisplatin, paclitaxel, epirubicin (CEP)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Cisplatin, paclitaxel, ifosfamide (CIP)
Number of subjects: 208
Study: 16642422

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 1148

Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 1148
Study: 14520145

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 316
Study: 10812310

Group type: EXPERIMENTAL
Intervention: Brief intervention at 16 weeks of gestation
Number of subjects: 123
Study: 9275424

Group type: EXPERIMENTAL
Intervention: Pelvic venous congestion syndrome (PVCSS) after tubal sterilization
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (normal women after sterilization)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Counts of macrophage in peritoneal fluid
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Plasma concentrations of ET‐1 and ANP
Number of subjects: 21
Study: 2001781

Group type: EXPERIMENTAL
Intervention: Postcard reminder
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (no postcard reminder)
Number of subjects: 4
Study: 7201809

Group type: EXPERIMENTAL
Intervention: Niludipine (60 or 120 mg daily for five consecutive weeks, with an initial dose of 20 mg three times on the first day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (administered for one week after the drug period)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Niludipine (single dose study)
Number of subjects: 8
Study: 30621689

Group type: EXPERIMENTAL
Intervention: Trigger system screening by trained nurses
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Trigger system screening
Number of subjects: 100
Study: 27886564

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) at the top tertile
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 536
Study: 25899566

Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion stimulation with one acupuncture needle for 4 weeks (once or twice weekly, total four to eight sessions)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion stimulation with one acupuncture needle
Number of subjects: 96

Group type: COMPARATOR
Intervention: Individualized verum acupuncture for 4 weeks (twice weekly, total eight sessions)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Individualized verum acupuncture
Number of subjects: 96
Study: 24682026

Group type: EXPERIMENTAL
Intervention: Balloon-expandable valve (Edwards Sapien XT)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Self-expandable valve (Medtronic CoreValve)
Number of subjects: 241
Study: 23016126

Group type: EXPERIMENTAL
Intervention: Pre-exercise hyperhydration (PEH) with 26 mL/kg bodyweight of a 130 mmol/L sodium solution
Number of subjects: 6

Group type: COMPARATOR
Intervention: Pre-exercise euhydration (PEE)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pre-exercise hyperhydration (PEH)
Number of subjects: 6
Study: 19095343

Group type: EXPERIMENTAL
Intervention: 1 mg micronised 17beta‐oestradiol plus 5 mg dydrogesterone (E/D group; n=18)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine oestrogens plus 5 mg medroxyprogesterone acetate (CEE/MPA group; n=14)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No treatment (control group; n=16)
Number of subjects: 48
Study: 17292929

Group type: EXPERIMENTAL
Intervention: Fiber containing bar (alginate and guar gum)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control bar
Number of subjects: 0
Study: 15159225

Group type: EXPERIMENTAL
Intervention: Stearic acid diet
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Trans fatty acids (TFA) diet
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TFA diet
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oleic acid diet
Number of subjects: 50
Study: 11678959

Group type: EXPERIMENTAL
Intervention: Clinical pharmacy services (intervention group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Routine clinic services (control group)
Number of subjects: 24
Study: 9503255

Group type: EXPERIMENTAL
Intervention: 10 mg ipsapirone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 30 mg +/- pindolol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 30 mg +/- pindolol and 10 mg ipsapirone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 7709763

Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin (100 U on alternate days) + oral calcium (1500 mg daily)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (untreated women)
Number of subjects: 47
Study: 3108346

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (intracoronary streptokinase)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 533
Study: 29605108

Group type: EXPERIMENTAL
Intervention: Video demonstration
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Telephone conversation with a radiographer
Number of subjects: 74

Group type: COMPARATOR
Intervention: Routine MRI preparation (appointment letter)
Number of subjects: 74
Study: 27780237

Group type: EXPERIMENTAL
Intervention: IPOS Neuro‐S8
Number of subjects: 134
Study: 24326236

Group type: EXPERIMENTAL
Intervention: Active rTMS-DLPFC
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 18
Study: 22129475

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering treatment (Systolic BP≤140mmHg within 1 hour)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Conservative treatment strategy (target systolic BP of 180mmHg)
Number of subjects: 152
Study: 19246136

Group type: EXPERIMENTAL
Intervention: Prenatal yoga programme (12-14 weeks, 3 sessions per week, 30 minutes each)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Prenatal yoga programme
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 88
Study: 19098331

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional coronary artery bypass grafting
Number of subjects: 0
Study: 14975534

Group type: EXPERIMENTAL
Intervention: Biventricular pacing (cardiac resynchronisation therapy or CRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11174538

Group type: COMPARATOR
Intervention: Composite resin control (Transbond XT)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Resin‐modified glass ionomer cement (Fuji Ortho LC)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Polyacid‐modified composite resin under dry conditions (Assure-dry)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Polyacid‐modified composite resin under wet conditions (Assure-wet)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: All adhesives
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Assure adhesive
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sample of extracted premolars
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Subset of sample (n = 34)
Number of subjects: 160
Study: 9552068

Group type: EXPERIMENTAL
Intervention: 153Sm‐EDTMP 1.0 mCi/kg
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 153Sm‐EDTMP 0.5 mCi/kg
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 7919941

Group type: EXPERIMENTAL
Intervention: Haloperidol doses of 40-45 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Haloperidol doses of 60-80 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Haloperidol doses greater than 100 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High haloperidol dosages
Number of subjects: 60
Study: 3275486

Group type: EXPERIMENTAL
Intervention: vincristine, dactinomycin, and cyclophosphamide (VAC)
Number of subjects: 686

Group type: COMPARATOR
Intervention: VAC + radiation
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: vincristine and dactinomycin (VA) + radiation
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: "pulse" VAC + radiation
Number of subjects: 686

Group type: COMPARATOR
Intervention: "pulse" VAC + Adriamycin (doxorubicin) + radiation
Number of subjects: 686
Study: 28832365

Group type: EXPERIMENTAL
Intervention: Intensive treatment arm (SBP < 120 mmHg)
Number of subjects: 4732

Group type: EXPERIMENTAL
Intervention: Standard treatment arm (SBP < 140 mmHg)
Number of subjects: 4732
Study: 23567785

Group type: EXPERIMENTAL
Intervention: Subglottic and gastric treatment suspension (polymyxin E 100 mg, vancomycin 1 g, and amphotericin B 500 mg) + intravenous cefotaxime (1 g 3 times a day for 4 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo + intravenous cefotaxime (1 g 3 times a day for 4 days)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Subglottic placebo and gastric treatment suspension + intravenous cefotaxime (1 g 3 times a day for 4 days)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Subglottic treatment suspension and gastric placebo + intravenous cefotaxime (1 g 3 times a day for 4 days)
Number of subjects: 44
Study: 23481888

Group type: EXPERIMENTAL
Intervention: Facilitated Tucking (FT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No Facilitated Tucking (Control)
Number of subjects: 20
Study: 20801180

Group type: EXPERIMENTAL
Intervention: Weight loss intervention for obese and overweight persons with anhedonia
Number of subjects: 82

Group type: COMPARATOR
Intervention: Weight loss intervention for obese and overweight persons without anhedonia
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Assessment of binge eating using the Binge Eating Scale (BES)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Assessment of eating behavior using the Three Factor Eating Questionnaire (TFEQ‐18)
Number of subjects: 82
Study: 18236347

Group type: EXPERIMENTAL
Intervention: Handsearching of 85 health care journals for RCTs and CCTs
Number of subjects: 18491

Group type: EXPERIMENTAL
Intervention: Handsearching of journals not indexed in Medline
Number of subjects: 18491
Study: 16628640

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha‐2b for 8 weeks (group A; n=34)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha‐2b for 12 weeks (group B; n=34)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha‐2b for 24 weeks (group C; n=34)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 8- and 12-week regimens
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (nonrandomized, n=30)
Number of subjects: 161
Study: 15006014

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone (CRO) 20 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 40
Study: 11491366

Group type: EXPERIMENTAL
Intervention: FSH/human menopausal gonadotropin combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FSH exclusively
Number of subjects: 0
Study: 9663214

Group type: EXPERIMENTAL
Intervention: Black patients
Number of subjects: 591

Group type: COMPARATOR
Intervention: White patients
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 591
Study: 8148352

Group type: COMPARATOR
Intervention: Baseline diet (36% kcal as fat: 15% saturated, 15% monounsaturated, and 6% polyunsaturated fat; 180 mg cholesterol.1000 kcal‐1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Corn oil diet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Olive oil diet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Canola oil diet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Plant-oil diets (olive, corn, canola)
Number of subjects: 15
Study: 3276228

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31715584

Group type: EXPERIMENTAL
Intervention: Postexercise glucose-fructose coingestion (1.5 g·kg‐1·hr‐1 carbohydrate)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Postexercise glucose-fructose coingestion (1.2 g·kg‐1·hr‐1 carbohydrate)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isocaloric glucose alone
Number of subjects: 16
Study: 30531253

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with everolimus-eluting stents
Number of subjects: 1905

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: Both PCI and CABG
Number of subjects: 1905
Study: 28855239

Group type: EXPERIMENTAL
Intervention: Closed-loop control (CLC) system
Number of subjects: 32
Study: 26274967

Group type: EXPERIMENTAL
Intervention: Rosenberg Self-Esteem Scale (SES)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Female Sexual Function Index (FSFI)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Posterior Trunk Symmetry Index (POTSI)
Number of subjects: 36
Study: 23577069

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 40,000 IU intravenously
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 21561959

Group type: EXPERIMENTAL
Intervention: Modafinil (up to 200 mg/day for 8 weeks)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 121

Group type: COMPARATOR
Intervention: Modafinil and Placebo
Number of subjects: 121
Study: 19935032

Group type: EXPERIMENTAL
Intervention: Transobturator tape
Number of subjects: 199

Group type: COMPARATOR
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 199
Study: 16513451

Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 25
Study: 12595969

Group type: EXPERIMENTAL
Intervention: Steroid+ (10 mg/day, n=17)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Steroid- (n=10)
Number of subjects: 27
Study: 10989265

Group type: EXPERIMENTAL
Intervention: MDMA (1.7 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9069450

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (300 to 900 mg/day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Dietary counseling
Number of subjects: 57
Study: 8439016

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine
Number of subjects: 30
Study: 3535000

Group type: EXPERIMENTAL
Intervention: Guar gum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31981307

Group type: EXPERIMENTAL
Intervention: Angle kappa-customized placement of SBL-3 MIOL
Number of subjects: 40

Group type: COMPARATOR
Intervention: Horizontal IOL placement (control group)
Number of subjects: 40
Study: 29846686

Group type: EXPERIMENTAL
Intervention: Calcium alginate sheet (CA) group
Number of subjects: 200

Group type: COMPARATOR
Intervention: No drug-eluting sheet (control) group
Number of subjects: 200
Study: 28719405

Group type: EXPERIMENTAL
Intervention: Empiric I therapeutic activities (348-939 MBq)
Number of subjects: 86
Study: 26180512

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 24862977

Group type: EXPERIMENTAL
Intervention: PM(2.5) increase (7.0 µg/m³)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CO increase (161.7 parts per billion)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: O₃ increase
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: SO₂ increase
Number of subjects: 49
Study: 22052264

Group type: EXPERIMENTAL
Intervention: BoNTA product 1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BoNTA product 2
Number of subjects: 20

Group type: COMPARATOR
Intervention: Frontalis Rating Scale (FRS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Frontalis Activity Measurement Standard (FMS)
Number of subjects: 20
Study: 19423029

Group type: EXPERIMENTAL
Intervention: Debridement plus topical antifungal nail lacquer
Number of subjects: 55

Group type: COMPARATOR
Intervention: Debridement alone
Number of subjects: 55
Study: 17374661

Group type: EXPERIMENTAL
Intervention: Egg treatment (640 mg/d additional cholesterol and 600 µg/d additional lutein + zeaxanthin)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Baseline treatment (no additional cholesterol or lutein + zeaxanthin)
Number of subjects: 22
Study: 15546428

Group type: EXPERIMENTAL
Intervention: Lifestyle education intervention
Number of subjects: 73
Study: 11476766

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (40 mg/d, p.o.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no testosterone supplementation)
Number of subjects: 40
Study: 9916606

Group type: EXPERIMENTAL
Intervention: Cefprozil 500 mg BID
Number of subjects: 278

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 500 mg/125 mg TID
Number of subjects: 278
Study: 7803354

Group type: EXPERIMENTAL
Intervention: Preoperative norfloxacin eyedrops
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 3054453

Group type: COMPARATOR
Intervention: Adriamycin (AD) alone
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: VP-16 plus lower dose adriamycin (VAD)
Number of subjects: 122
Study: 31733813

Group type: EXPERIMENTAL
Intervention: Structured six-session psychological treatment
Number of subjects: 384

Group type: COMPARATOR
Intervention: Routine antenatal health care and three monthly phone calls
Number of subjects: 384
Study: 29874649

Group type: EXPERIMENTAL
Intervention: EPS+ bacterial pellets
Number of subjects: 2

Group type: COMPARATOR
Intervention: EPS- bacterial pellets
Number of subjects: 2
Study: 28710902

Group type: EXPERIMENTAL
Intervention: Single-session cognitive behavioural therapy intervention including a risk communication module
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200